Cargando…
Challenges in Permeability Assessment for Oral Drug Product Development
Drug permeation across the intestinal epithelium is a prerequisite for successful oral drug delivery. The increased interest in oral administration of peptides, as well as poorly soluble and poorly permeable compounds such as drugs for targeted protein degradation, have made permeability a key param...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10609725/ https://www.ncbi.nlm.nih.gov/pubmed/37896157 http://dx.doi.org/10.3390/pharmaceutics15102397 |
_version_ | 1785128080554065920 |
---|---|
author | Koziolek, Mirko Augustijns, Patrick Berger, Constantin Cristofoletti, Rodrigo Dahlgren, David Keemink, Janneke Matsson, Pär McCartney, Fiona Metzger, Marco Mezler, Mario Niessen, Janis Polli, James E. Vertzoni, Maria Weitschies, Werner Dressman, Jennifer |
author_facet | Koziolek, Mirko Augustijns, Patrick Berger, Constantin Cristofoletti, Rodrigo Dahlgren, David Keemink, Janneke Matsson, Pär McCartney, Fiona Metzger, Marco Mezler, Mario Niessen, Janis Polli, James E. Vertzoni, Maria Weitschies, Werner Dressman, Jennifer |
author_sort | Koziolek, Mirko |
collection | PubMed |
description | Drug permeation across the intestinal epithelium is a prerequisite for successful oral drug delivery. The increased interest in oral administration of peptides, as well as poorly soluble and poorly permeable compounds such as drugs for targeted protein degradation, have made permeability a key parameter in oral drug product development. This review describes the various in vitro, in silico and in vivo methodologies that are applied to determine drug permeability in the human gastrointestinal tract and identifies how they are applied in the different stages of drug development. The various methods used to predict, estimate or measure permeability values, ranging from in silico and in vitro methods all the way to studies in animals and humans, are discussed with regard to their advantages, limitations and applications. A special focus is put on novel techniques such as computational approaches, gut-on-chip models and human tissue-based models, where significant progress has been made in the last few years. In addition, the impact of permeability estimations on PK predictions in PBPK modeling, the degree to which excipients can affect drug permeability in clinical studies and the requirements for colonic drug absorption are addressed. |
format | Online Article Text |
id | pubmed-10609725 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-106097252023-10-28 Challenges in Permeability Assessment for Oral Drug Product Development Koziolek, Mirko Augustijns, Patrick Berger, Constantin Cristofoletti, Rodrigo Dahlgren, David Keemink, Janneke Matsson, Pär McCartney, Fiona Metzger, Marco Mezler, Mario Niessen, Janis Polli, James E. Vertzoni, Maria Weitschies, Werner Dressman, Jennifer Pharmaceutics Review Drug permeation across the intestinal epithelium is a prerequisite for successful oral drug delivery. The increased interest in oral administration of peptides, as well as poorly soluble and poorly permeable compounds such as drugs for targeted protein degradation, have made permeability a key parameter in oral drug product development. This review describes the various in vitro, in silico and in vivo methodologies that are applied to determine drug permeability in the human gastrointestinal tract and identifies how they are applied in the different stages of drug development. The various methods used to predict, estimate or measure permeability values, ranging from in silico and in vitro methods all the way to studies in animals and humans, are discussed with regard to their advantages, limitations and applications. A special focus is put on novel techniques such as computational approaches, gut-on-chip models and human tissue-based models, where significant progress has been made in the last few years. In addition, the impact of permeability estimations on PK predictions in PBPK modeling, the degree to which excipients can affect drug permeability in clinical studies and the requirements for colonic drug absorption are addressed. MDPI 2023-09-28 /pmc/articles/PMC10609725/ /pubmed/37896157 http://dx.doi.org/10.3390/pharmaceutics15102397 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Koziolek, Mirko Augustijns, Patrick Berger, Constantin Cristofoletti, Rodrigo Dahlgren, David Keemink, Janneke Matsson, Pär McCartney, Fiona Metzger, Marco Mezler, Mario Niessen, Janis Polli, James E. Vertzoni, Maria Weitschies, Werner Dressman, Jennifer Challenges in Permeability Assessment for Oral Drug Product Development |
title | Challenges in Permeability Assessment for Oral Drug Product Development |
title_full | Challenges in Permeability Assessment for Oral Drug Product Development |
title_fullStr | Challenges in Permeability Assessment for Oral Drug Product Development |
title_full_unstemmed | Challenges in Permeability Assessment for Oral Drug Product Development |
title_short | Challenges in Permeability Assessment for Oral Drug Product Development |
title_sort | challenges in permeability assessment for oral drug product development |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10609725/ https://www.ncbi.nlm.nih.gov/pubmed/37896157 http://dx.doi.org/10.3390/pharmaceutics15102397 |
work_keys_str_mv | AT koziolekmirko challengesinpermeabilityassessmentfororaldrugproductdevelopment AT augustijnspatrick challengesinpermeabilityassessmentfororaldrugproductdevelopment AT bergerconstantin challengesinpermeabilityassessmentfororaldrugproductdevelopment AT cristofolettirodrigo challengesinpermeabilityassessmentfororaldrugproductdevelopment AT dahlgrendavid challengesinpermeabilityassessmentfororaldrugproductdevelopment AT keeminkjanneke challengesinpermeabilityassessmentfororaldrugproductdevelopment AT matssonpar challengesinpermeabilityassessmentfororaldrugproductdevelopment AT mccartneyfiona challengesinpermeabilityassessmentfororaldrugproductdevelopment AT metzgermarco challengesinpermeabilityassessmentfororaldrugproductdevelopment AT mezlermario challengesinpermeabilityassessmentfororaldrugproductdevelopment AT niessenjanis challengesinpermeabilityassessmentfororaldrugproductdevelopment AT pollijamese challengesinpermeabilityassessmentfororaldrugproductdevelopment AT vertzonimaria challengesinpermeabilityassessmentfororaldrugproductdevelopment AT weitschieswerner challengesinpermeabilityassessmentfororaldrugproductdevelopment AT dressmanjennifer challengesinpermeabilityassessmentfororaldrugproductdevelopment |